| Generic Name |
Belantamab mafodotin-blmf |
| Brand Name |
Blenrep™ |
| Payment Category |
Medicare Part B |
| Year Introduced |
2020 |
| Type of Drug |
BMCA-directed antibody and microtubule inhibitor conjugate |
| Manufacturer |
GlaxoSmithKline |
| Medical Affairs Questions (date verified) |
877.475.6448 |
| Coverage & Reimbursement Questions |
877.423.6597 |
| HCPCS |
Not yet assigned |
| Billing Unit |
Not yet assigned |
| Medicare Payment Limit (Effective January 1, 2021) |
Not yet determined |
FDA-Approved Indication(s)
- Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. (8/06/20)
|
| Approved Indication(s) with Orphan Drug Status |
None |
| ICD-10 Code(s) for Labeled Indication(s) |
Multiple myeloma [C90.x]; |
